The HRI-regulated transcription factor ATF4 activates BCL11A transcription to silence fetal hemoglobin expression

Abstract excerpt

Reactivation of fetal hemoglobin remains a critical goal in the treatment of patients with sickle cell disease and β-thalassemia. Previously, we discovered that silencing of the fetal γ-globin gene requires the erythroid-specific eIF2α kinase heme-regulated inhibitor (HRI), suggesting that HRI might present a pharmacologic target for raising fetal hemoglobin levels. Here, via a CRISPR-Cas9-guided loss-of-function...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Hemoglobinopathies and Related Disorders
• Share to Prenatal Screening and Diagnostics
• Share to RNA modifications and cancer